Stock Track | Recursion Pharmaceuticals Soars 7.93% in Pre-market on Strong Q4 Earnings Beat

Stock Track
02/25

Recursion Pharmaceuticals, Inc. (RXRX) saw its stock price surge 7.93% in pre-market trading on Wednesday, following the release of its fourth-quarter financial results.

The biotechnology company reported Q4 operating revenue of $35.351 million, significantly exceeding the IBES estimate of $24.6 million. Additionally, Recursion's Q4 net loss of $108.124 million was narrower than the estimated loss of $131.1 million, indicating better-than-expected financial performance.

The positive earnings surprise, with both revenue and net income beating analyst expectations, appears to be driving investor optimism and the substantial pre-market price increase.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10